Botulinum Toxin for the Facial Cosmetic Surgeon

Beer K Yohn M Closter J . A double-blinded, placebo-controlled study of Botox for the treatment of subjects with chin rhytids. J Drugs Dermatol. 2005;4:417–422.

Keen M Blitzer A Aviv J , Botulinum toxin A for hyperkinetic facial lines: Results of a double-blind, placebo-controlled study. Plast Reconstr Surg. 1994;94:94–99.

Carruthers JA Lowe NJ Menter MA , A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840–849.

Gassner HG Brissett AE Otley CC , Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006;81:1023–1028.

Erbguth FJ Naumann M . Historical aspects of botulinum toxin: Justinus Kerner (1786–1862) and the “sausage poison.” Neurology. 1999;53:1850–1853.

Kerner J . Neue Beobachtungen über die in Württemberg so haüfig vorfallenden tödlichen Vergiftungen durch den Genuss geraücherter Würste. Tübingen, Germany: Osiander; 1820.

Kerner J . Das Fettgift oder die Fettsaüre und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Stuttgart, Germany: Cotta; 1822.

Scott AB Rosenbaum A Collins CC . Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924–927.

Scott AB . Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–1049.

Scott AB Kennedy RA Stubbs HA . Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103:347–350.

Carruthers A Carruthers J . History of the cosmetic use of Botulinum A exotoxin. Dermatol Surg. 1998;24:1168–1170.

Black JD Dolly JO . Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol. 1986;103:535–544.

Hughes R Whaler BC . Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin. J Physiol. 1962;160:221–233.

Rizo J Sudhof TC . Mechanics of membrane fusion. Nat Struct Biol. 1998;5:839–842.

Aoki KR Guyer B . Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(suppl 5):21–29.

Schiavo G Rossetto O Catsicas S , Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem. 1993;268:23784–23787.

Schiavo G Benfenati F Poulain B , Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992;359:832–835.

Scott AB Suzuki D . Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord. 1988;3:333–335.

Chertow DS Tan ET Maslanka SE , Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA. 2006;296:2476–2479.

McLellan K Das RE Ekong TA Sesardic D . Therapeutic botulinum type A toxin: Factors affecting potency. Toxicon. 1996;34:975–985.

Rosales RL Bigalke H Dressler D . Pharmacology of botulinum toxin: Differences between type A preparations. Eur J Neurol. 2006;13(suppl 1):2–10.

BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex: Advanced Toxin Technology [product monograph]. Irvine, Calif: Allergan Inc; 1998. No. Rx 9161.

Alam M Dover JS Arndt KA . Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: A double-blind, randomized controlled trial. Arch Dermatol. 2002;138:510–514.

Hexsel DM De Almeida AT Rutowitsch M , Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg. 2003;29:523–529.

Alam M Yoo SS Wrone DA White LE Kim JY . Sterility assessment of multiple use botulinum A exotoxin vials: A prospective simulation. J Am Acad Dermatol. 2006;55:272–275.

De Almeida AR Trindade Kadunc BV Di Chiacchio N Neto DR . Foam during reconstitution does not affect the potency of botulinum toxin type A. Dermatol Surg. 2003;29:530–531.

Carruthers A Carruthers J Cohen J . Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: Does it matter? Dermatol Surg. 2007;33:S97–S104.

Carruthers A Bogle M Carruthers JD , A randomized, evaluator-blinded, two-center study of the safety and effect of volume on the diffusion and efficacy of botulinum toxin type A in the treatment of lateral orbital rhytides. Dermatol Surg. 2007;33:567–571.

Hsu TS Dover JS Arndt KA . Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol. 2004;140:1351–1354.

Fagien S . Botulinum toxin type A for facial aesthetic enhancement: Role in facial shaping. Plast Reconstr Surg. 2003;112:6S–18S.

Kane MA . The functional anatomy of the lower face as it applies to rejuvenation via chemodenervation. Facial Plast Surg. 2005;21:55–64.

Lee H Saladi RN Fox JL . Cohort study on patient response to botulinum toxin cosmetic therapy. J Cosmet Dermatol. 2008;7:39–42.

Levy JL Pons F Jouve E . Management of the ageing eyebrow and forehead: An objective dose-response study with botulinum toxin. J Eur Acad Dermatol Venereol. 2006;20:711–716.

Carruthers A Carruthers J Cohen J . A prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatol Surg. 2003;29:461–467.

Rohrich RJ Janis JE Fagien S Stuzin JM . The cosmetic use of botulinum toxin. Plast Reconstr Surg. 2003;112:177S–188S.

Carruthers A Carruthers J . Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg. 1998;24:1189–1194.

Loos BM Maas CS . Relevant anatomy for botulinum toxin facial rejuvenation. Facial Plast Surg Clin North Am. 2003;11:439–443.

Rzany B Ascher B Fratila A Monheit GD Talarico S Sterry W . Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol. 2006;142:320–326.

Carruthers A Carruthers J Said S . Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31:414–422.

Carruthers A Carruthers J . Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005;31:1297–1303.

Frankel AS Kamer FM . Chemical browlift. Arch Otolaryngol Head Neck Surg. 1998;124:321–323.

Scheinfeld N . The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face. Dermatol Online J. 2005;11:9.

Lowe NJ Ascher B Heckmann M Kumar C Fraczek S Eadie N . Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg. 2005;31:257–262.

Ahn MS Catten M Maas CS . Temporal brow lift using botulinum toxin A. Plast Reconstr Surg. 2000;105:1129–1135.

Matarasso SL Matarasso A . Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg. 2001;108:208–214.

Carruthers J Carruthers A . Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg. 2003;29:468–476.

Flynn TC Carruthers JA . Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg. 2001;27:703–708.

Fagien S . Temporary management of upper lid ptosis, lid malposition, and eyelid fissure asymmetry with botulinum toxin type A. Plast Reconstr Surg. 2004;114:1892–1902.

Tamura BM Odo MY Chang B Cuce LC Flynn TC . Treatment of nasal wrinkles with botulinum toxin. Dermatol Surg. 2005;31:271–275.

Semchyshyn N Sengelmann RD . Botulinum toxin A treatment of perioral rhytides. Dermatol Surg. 2003;29:490–495.

Levy PM . The “Nefertiti lift”: A new technique for specific re-contouring of the jawline. J Cosmet Laser Ther. 2007;9:249–252.

Carruthers J Carruthers A . Practical cosmetic Botox techniques. J Cutan Med Surg. 1999;3(suppl 4):S49–S52.

Kane MA . Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast Reconstr Surg. 1999;103:656–663.

Choe SW Cho WI Lee CK Seo SJ . Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg. 2005;31:502–507.

Kim JH Shin JH Kim ST Kim CY . Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle. Plast Reconstr Surg. 2007;119:711–717.

Ahn J Horn C Blitzer A . Botulinum toxin for masseter reduction in Asian patients. Arch Facial Plast Surg. 2004;6:188–191.

Yu CC Chen PK Chen YR . Botulinum toxin A for lower facial contouring: A prospective study. Aesthetic Plast Surg. 2007;31:445–451.

Kwon JS Kim ST Jeon YM Choi JH . Effect of botulinum toxin type A injection into human masseter muscle on stimulated parotid saliva flow rate. Int J Oral Maxillofac Surg. 2009;38:316–320.

Wilson AM . Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg. 2006;117:1758–1766.

Gassner HG Sherris DA Friedman O . Botulinum toxin-induced immobilization of lower facial wounds. Arch Facial Plast Surg. 2009;11:140–142.

Gassner HG Sherris DA . Chemoimmobilization: Improving predictability in the treatment of facial scars. Plast Reconstr Surg. 2003;112:1464–1466.

Newman WJ Davis TL Padaliya BB , Botulinum toxin type A therapy during pregnancy. Mov Disord. 2004;19:1384–1385.

Wollina U Konrad H . Managing adverse events associated with botulinum toxin type A: A focus on cosmetic procedures. Am J Clin Dermatol. 2005;6:141–150.

Harth W Linse R . Botulinophilia: Contraindication for therapy with botulinum toxin. Int J Clin Pharmacol Ther. 2001;39:460–463.

Carruthers J Fagien S Matarasso SL . Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg. 2004;114:1S–22S.

Gobel H . Botulinum toxin in migraine prophylaxis. J Neurol. 2004;251(suppl 1):I8–I11.

Greene P Fahn S Diamond B . Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213–217.

Dertzbaugh MT West MW . Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine. 1996;14:1538–1544.

Fiacchino F Grandi L Soliveri P Carella F Bricchi M . Sensitivity to vecuronium after botulinum toxin administration. J Neurosurg Anesthesiol. 1997;9:149–153.

Klein AW . Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003;29:549–556.